Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space, extracellular matrix |
Domain |
PF00045 Hemopexin PF00413 Matrixin PF01471 Putative peptidoglycan binding domain |
Function |
Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. Activates procollagenase. |
Biological Process |
GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0030574 collagen catabolic process GO:0032963 collagen metabolic process GO:0043062 extracellular structure organization GO:0044236 multicellular organism metabolic process GO:0044243 multicellular organism catabolic process GO:0044259 multicellular organismal macromolecule metabolic process |
Molecular Function |
GO:0004175 endopeptidase activity GO:0004222 metalloendopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0008236 serine-type peptidase activity GO:0008237 metallopeptidase activity GO:0017171 serine hydrolase activity |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix |
KEGG | - |
Reactome |
R-HSA-1592389: Activation of Matrix Metalloproteinases R-HSA-1442490: Collagen degradation R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1474244: Extracellular matrix organization R-HSA-5683057: MAPK family signaling cascades R-HSA-5687128: MAPK6/MAPK4 signaling R-HSA-162582: Signal Transduction |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MMP10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MMP10 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MMP10 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MMP10 in various data sets.
|
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP10. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MMP10 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MMP10 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MMP10 |
Name | matrix metallopeptidase 10 |
Aliases | STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ...... |
Chromosomal Location | 11q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MMP10 collected from DrugBank database. |
Details on drugs targeting MMP10.
|